Comisión Nacional del Mercado de Valores Att. Director del Área de Mercados C/Edison núm. 4

28006 Madrid

Colmenar Viejo (Madrid), a 10 de enero de 2017

De conformidad con lo previsto en el artículo 228 del Texto Refundido de la Ley de Mercado de Valores, por la presente se procede a comunicar el siguiente HECHO RELEVANTE:

"Se adjunta presentación corporativa en inglés que estará disponible a partir de la tarde de hoy también en la página web de la Compañía www.pharmamar.com."

Pharma Mar S.A. Avda. de los Reyes, 1

P.I. La Mina

28770 Colmenar Viejo (Madrid) Spain www.pharmamar.com

CORPORATE PRESENTATION January 2017 Disclaimer

This document includes only summary information and is not intended to be comprehensive. This document includes "forward-looking statements" that are based on Management's current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the success of the Company's research strategy; the applicability of discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether the Company's potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from the government, private healthcare insurers and third-party payers; and the uncertainties as to the extent of future government regulation of the pharmaceutical business. Therefore those statements involve risks and uncertainties beyond the Company's control and actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.

Investment Highlights

A leader in the development & commercialization of marine-derived oncology drugs

  • Multinational biotechnology company developing marine-derived and novel MoA oncology drugs

    • Fully integrated biotechnology company - from discovery to commercialization

    • Highly productive R&D organization (1 approved drug and 2 in late stage development)

  • Established oncology sales force in Europe:

    • Strong partners in the US (Janssen), Europe (Chugai), and Japan (Taiho, Chugai)

  • Late stage development pipeline driving future value

    • Lurbinectedin (PM1183): Next generation Yondelis®

    • Aplidin®: Positive pivotal data in Multiple Myeloma with an EMA NDA filed in Sept 2016

  • Track record of operational excellence with a strong financial position

    • Company with growing revenues and robust cash flow

    • Headquartered and traded in Madrid

    • C. €620m market cap (as of 12/21/16)

    • €63.5m in cash and cash equivalents (9 months 2016)*

    • €16m operating cash burn + debt service (9 months 2016)

* Proforma for Chugai Lurbinectedin partnership, €30mn upfront, announced Dec 22nd 2016

Pharma Mar SA published this content on 10 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 10 January 2017 14:53:13 UTC.

Original documenthttps://www.pharmamar.com/2017/01/10/se-remite-nueva-presentacion-corporativa-en-ingles-que-se-colgara-en-la-pagina-web-de-la-compania/

Public permalinkhttp://www.publicnow.com/view/8F62508379AE996F98D22B6ECD83EBB25EA7CEB9